Business Wire

SHIPPEO

Share
Shippeo’s Shipment Tracking ETA Accuracy Leaps Forward With a Giant 32% Improvement

Shippeo , a leading provider of global shipment visibility, has achieved a significant advancement in its predictive shipment ETA performance, aided by investments in new AI/ML infrastructure and sophisticated algorithms. As a result, shippers and logistics service providers are seeing improved accuracy and reliability of estimated times of arrival (ETAs) of their shipments, thereby increasing the efficiency and predictability of their supply chains.

The recent challenges caused by major supply chain disruptions have reaffirmed the need for organisations to improve shipment traceability on a global scale. Although it has never been easier to track shipments travelling throughout the world in near real-time thanks to more affordable devices and better connectivity, the type of data that supply chain management values is changing.

Shippeo’s Chief Product Officer, Anand Medepalli, says: “The question supply chain managers are asking themselves is shifting from ‘where is my shipment’ at the macro level to a more granular ‘When will it arrive at the next stop?’ and ‘Are there any risks of a delay?’”. This means that the ability to predict shipment ETAs at a very granular level is increasingly becoming a must-have, critical capability for shippers.

This improved ETA brings a range of benefits to manufacturers. Shippeo customers report that having accurate ETA predictions for shipment arrival times improves team productivity at key delivery sites, while boosting KPI performance, increasing sales and, of course, raising customer satisfaction levels. At the same time, these manufacturers, many of which are operating globally, are decreasing stock-outs or production line halts by as much as 76%, as well as reducing late penalties by 25%, dwell times by 30% and reducing unexpected freight costs.

As with any algorithm, ETA accuracy depends heavily on the quality of data inputted, which is why Shippeo’s core R&D focus is to continually enhance the accuracy and reliability of the data feeding the ETA predictions. In its latest third release, in addition to data quality, the company has revamped its machine learning (ML) infrastructure, as well as the methodologies and models its data scientists and ML engineers use. The result is an impressive 32% improvement in ETA accuracy up to 48 hours before a scheduled delivery.

“This is really exciting for us given that several of our customers, including Renault Group, one of the world’s largest automotive manufacturers, have already told us that our ETA is impressive,” says Medepalli.

“Shippeo invests a lot in continually improving its ETA calculator algorithm, taking our feedback as users into account,” says Renan Filleur, Renault Group’s General Manager of Parts Logistic Operations and Performance. “ETA reliability results are an important focus and are made visible, which greatly supports Renault Group’s choice of Shippeo’s real-time visibility platform. This reliability is a critical element for any major industrial customer like Renault due to the genuine value it generates for the business.”

Shippeo is also the only real-time transportation visibility platform vendor offering contractual guarantees on its ETA accuracy, as well as carrier onboarding speed and high tracking rates. “The performance of our ETA model gives us the confidence to guarantee high accuracy for all of our customers or we give their money back,” explains Medepalli, “which means a guaranteed time to value for every customer. This relentless focus on customer satisfaction is what differentiates us from our competition.”

The enhanced ETA algorithm is available now for all Shippeo platform users.

Learn more

- Ends -

About Shippeo (https://www.shippeo.com ) LinkedIn , Facebook , Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Announces Sale of SPX FLOW to ITT Inc.5.12.2025 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced the signing by an affiliate of Lone Star Fund XI, LP of a definitive agreement to sell SPX FLOW, Inc. (“SPX FLOW”), a leading provider of highly engineered equipment and process technologies for attractive end markets including industrial, health and nutrition, to ITT Inc. (NYSE: ITT) for $4.775 billion in cash and shares of common stock. Based in Charlotte, N.C., SPX FLOW focuses on process technologies delivering mixing, blending, fluid handling, separation, thermal heat transfer and other solutions integral to industrial, health and nutrition markets. The company has operations in more than 25 countries and sales in more than 140 countries. In partnership with Lone Star, SPX FLOW has focused on improving its sales execution and operating platform, while ensuring high quality and innovative product development. The management team has improved the company’s commercial organization and executed growth initiatives to build its presence in e

AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGACompany Named ANV Group Holdings Ltd.5.12.2025 13:00:00 CET | Press release

Strategic Transaction Unlocks Value for AmTrust and Positions ANV Group Holdings for Accelerated GrowthFormer AmTrust President Adam Karkowsky Leading ANV Group Holdings as Chairman and CEO AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV S

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body5.12.2025 07:00:00 CET | Press release

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the improvement in cellulite appearance), firmness, lift, projection, and contour Sculptra’s versatility and new indication allow practitioners to shift patient treatment goals beyond rejuvenation toward enhancement, meeting evolving patient needs The certification validates Sculptra’s safety performance, efficacy, and quality, reinforcing Galderma’s commitment to innovation and meeting evolving patient needs Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its

Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 02:40:00 CET | Press release

4x World’s Best Heli-Skiing Operation near Terrace, BC Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge f

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye